Biotherapeutics News and Research

RSS

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced that it has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population.

2 Nov 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

Protein Discovery and New Objective sign co-marketing and development agreement

Protein Discovery, Inc. and New Objective, Inc. today announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry ("top down" proteomics).

22 Oct 2009

BDI Pharma's expanded portfolio boosts third-quarter revenue

BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced that revenue for the third quarter of 2009 continued to sustain the momentum experienced during the first two fiscal quarters of this year. A primary driver of third quarter revenue was the exceptional success of the company's expanded portfolio of specialty biotherapeutics.

22 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement. The CI Index as a whole trades for 10% of estimated future revenues.

21 Oct 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN® produced using advances in manufacturing technology.

19 Oct 2009

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Pfizer Inc today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.

19 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

Talecris Biotherapeutics Holdings to raise $550 million through private placement

Talecris Biotherapeutics Holdings Corp. today announced that it has commenced an offering through a private placement of $550 million aggregate principal amount of senior notes due 2016 (the “Notes”). Talecris intends to use the proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, and to pay related fees and expenses.

13 Oct 2009

Talecris Biotherapeutics closes initial public offering of common stock

Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) (“Talecris” or the “Company”) today announced the closing on October 6 of its initial public offering of shares of common stock, which was priced on September 30 at a public offering price of $19.00 per share.

8 Oct 2009

aTyr Pharma to discuss aminoacyl tRNA synthetases at the BioPartnering Europe Conference

aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring proteins as biotherapeutics, will present at the BioPartnering Europe Conference in London on Monday October 12. Jeff Watkins, CEO of aTyr Pharma, will provide an overview of aTyr Pharma's technology, product engine, and lead program based on naturally occurring resected proteins of the tRNA synthetases.

7 Oct 2009

CSL Behring LEAD program invites grant requests from organizations assisting people with rare diseases

CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.

7 Oct 2009

Scientific Advisory Board to provide guidance to support the development of FST-100

Foresight Biotherapeutics announced today the formation of its scientific advisory board to provide guidance to the company for the development of it’s lead product FST-100, a novel formulation of dexamethasone that includes povidone-iodine. Foresight’s Scientific Advisory Board is comprised of leaders in the field of Ophthalmology.

1 Oct 2009

Scarab Genomics releases new E. Coli strain

ScarabXpress is the latest strain in the multiple-deletion series (MDS) of Scarab Genomics Clean Genome® E. coli. Based on the MDS™42 strain, ScarabXpress T7lac contains a chromosomal copy of the T7 RNA polymerase gene expressed from a unique, tightly controlled lac promoter.

29 Sep 2009

Dyax to present an update of its clinical development programs

Dyax Corp., a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Fourth Annual JMP Securities Healthcare Focus Conference, being held October 5-6th at The New York Palace Hotel in New York City, NY.

25 Sep 2009

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

24 Sep 2009

Biotherapeutics News and Research

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

Protein Discovery and New Objective sign co-marketing and development agreement

BDI Pharma's expanded portfolio boosts third-quarter revenue

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

Oxygen Biotherapeutics announces its expanded product development plan

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Talecris Biotherapeutics Holdings to raise $550 million through private placement

Talecris Biotherapeutics closes initial public offering of common stock

aTyr Pharma to discuss aminoacyl tRNA synthetases at the BioPartnering Europe Conference

CSL Behring LEAD program invites grant requests from organizations assisting people with rare diseases

Scientific Advisory Board to provide guidance to support the development of FST-100

Scarab Genomics releases new E. Coli strain

Dyax to present an update of its clinical development programs

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring